Research and development screener Excel - if you came here looking for a structured way to rank companies by the dollars they pour into innovation, this guide is for you. Q1 2026 earnings season is wrapping up, hyperscalers have spent the last six months arguing about whether the AI capex bill will ever pay back, and advisors are quietly building watchlists of companies whose R&D budgets are actually expanding the moat rather than just burning cash. A research and development screener built in Excel with MarketXLS formulas is the cleanest way to do this work in 2026, and the template attached below gives you everything you need to get started.
This post walks through what R&D intensity is, why it matters in a year dominated by AI capex headlines, how to build the screener in Excel, which MarketXLS formulas to plug in, and how to interpret what comes out. Both Excel files are linked at the bottom: a static sample version with snapshot data and a live formula version that updates every time you hit refresh.
What This Research and Development Screener Excel Template Delivers
The template ranks 30 large-cap names from Information Technology, Communication Services, Consumer Discretionary, Healthcare, and Industrials across four dimensions:
| Dimension | What It Measures | Why It Matters |
|---|---|---|
| R&D Intensity | R&D expense / Revenue | Reveals the share of every revenue dollar reinvested in research |
| Profitability | Gross margin + Operating margin | Confirms research is funded from a durable margin base |
| Growth | Revenue growth YoY | Validates that research is converting into top-line momentum |
| Capital Efficiency | Return on invested capital (ROIC) | Confirms management is not torching capital on the way |
These four pillars roll up into a composite Innovation Moat Score from 0 to 100, tiered into four categories so you can see at a glance which names show the strongest research-funded moat story.
Why R&D Intensity Matters in May 2026
May 2026 sits at the intersection of three forces that make the research and development screener Excel work especially timely:
- AI capex fatigue. Hyperscalers have spent a record amount on AI infrastructure over the past year, and the question across every Q1 2026 earnings call has been the same: when does it pay back? Companies that pair AI spending with rising gross margin and rising revenue per dollar of R&D are pulling away from the pack.
- Tariff-driven margin pressure. Several industrials and consumer-discretionary names saw gross margin compression in Q1 from tariff exposure. R&D intensity is one of the cleanest tells for which names have the pricing power to pass costs through versus which are absorbing them.
- Earnings season filtering. With Q1 2026 reports largely in the books, advisors are filtering through who beat-and-raised guidance versus who guided down. R&D-to-revenue trajectory adds a forward-looking lens that the trailing earnings beat alone misses.
R&D intensity is one of the oldest quality screens in equity research. Companies that consistently outspend peers on R&D as a share of revenue, while sustaining gross margin and ROIC, tend to compound earnings power over long periods. That said, the relationship is not mechanical. Heavy R&D paired with falling margins can signal a research treadmill, not a moat. The screener combines all four lenses to surface only the names where the story holds up.
How R&D Intensity Is Defined
The core ratio is straightforward:
R&D Intensity = R&D Expense / Revenue
A semiconductor name spending 25% of revenue on R&D has a different cost structure than a packaged-goods name spending 1.5%, so the screener uses sector context rather than a single threshold. In MarketXLS, the R&D-to-revenue ratio is available directly via:
=HF_RANDD_EXPENSE_AS_PERCENTAGE_OF_REVENUE("AAPL", 2025)
That formula returns the fiscal-year 2025 R&D as percentage of revenue figure for Apple. Pair it with raw dollar R&D to understand the absolute scale of the spend:
=HF_RANDD_EXPENSES("AAPL", 2025)
The dollar value matters because R&D efficiency is a function of the platform. A $50 billion R&D budget at a hyperscaler reaches into more product categories than a $5 billion budget at a single-product specialist, even at the same intensity ratio.
The 30-Name Watchlist Inside the Template
The research and development screener Excel template ships with 30 large-cap names across the sectors where R&D investment dominates the operating profile:
| Sector | Names |
|---|---|
| Information Technology | NVDA, AVGO, AMD, INTC, QCOM, MU, AMAT, LRCX, MSFT, ORCL, CRM, NOW, ADBE, PLTR |
| Communication Services | GOOGL, META, NFLX |
| Consumer Discretionary | AMZN, TSLA |
| Healthcare | LLY, MRK, PFE, REGN, VRTX, ISRG, BSX |
| Industrials | LMT, RTX, GE, HON |
The list intentionally mixes high-R&D semis and software with lower-intensity industrials and pharma so the screener surfaces relative differences. You can edit the watchlist freely. The MarketXLS formulas resolve symbol by symbol, so adding or replacing tickers takes seconds.
Building the Screener Step by Step
Step 1: Pull R&D Intensity
The first column of the dashboard is the headline ratio. In the template:
=HF_RANDD_EXPENSE_AS_PERCENTAGE_OF_REVENUE("NVDA", 2025) / 100
The /100 converts the percentage to a decimal so the cell can be formatted as a percent. The same formula works for any name on the watchlist. To pull multiple fiscal years, change the second argument:
=HF_RANDD_EXPENSE_AS_PERCENTAGE_OF_REVENUE("NVDA", 2021)
=HF_RANDD_EXPENSE_AS_PERCENTAGE_OF_REVENUE("NVDA", 2022)
=HF_RANDD_EXPENSE_AS_PERCENTAGE_OF_REVENUE("NVDA", 2023)
=HF_RANDD_EXPENSE_AS_PERCENTAGE_OF_REVENUE("NVDA", 2024)
=HF_RANDD_EXPENSE_AS_PERCENTAGE_OF_REVENUE("NVDA", 2025)
That five-year strip lives on the R&D Trend sheet of the template and tells you whether the company is leaning into research, holding it flat, or harvesting prior investment.
Step 2: Layer in Profitability
R&D without margin is a research treadmill. The screener pairs intensity with gross and operating margin:
=GrossMargin("NVDA")
=OperatingMargin("NVDA")
A name spending 25% of revenue on R&D while sustaining 70%+ gross margin and 30%+ operating margin has the structural cushion to keep investing. The same intensity with a 30% gross margin tells a very different story.
Step 3: Confirm Growth
The next test is whether the research is converting into top-line growth:
=RevenueGrowth("NVDA")
The screener uses this as a 0-to-100 sub-score, scaled against a 40% growth target. Names below the target score proportionally; names well above max out at 100. Combined with R&D intensity, this is where the genuine compounders separate from the laggards.
Step 4: Test Capital Efficiency
Heavy R&D combined with weak ROIC means the research dollars are not earning their keep:
=ReturnOnInvestedCapitalOneYear("NVDA")
The MarketXLS function returns the last-twelve-month ROIC. The screener uses 30% as a high-quality ceiling; anything above scores 100. Healthcare names with strong drug franchises and IT names with platform economics tend to cluster near the top.
Step 5: Build the Composite Score
The composite Innovation Moat Score combines all four pillars using weights you set in the Inputs sheet:
Composite = R&D Score * w1 + Profitability Score * w2
+ Growth Score * w3 + Capital Efficiency Score * w4
Default weights are 30% R&D intensity, 25% profitability, 25% growth, and 20% capital efficiency. You can shift them to suit your style. Investors who prize cash generation can boost the profitability and capital efficiency weights; those hunting next-cycle leaders can boost growth.
The Excel formula that builds the composite in the template references the Inputs sheet directly:
=(MIN(MAX(E4,0)/0.30,1)*100)*Inputs!$C$11
+ ((MIN(MAX(G4,0)/0.80,1)*50)+(MIN(MAX(H4,0)/0.40,1)*50))*Inputs!$C$12
+ (MIN(MAX(I4,0)/0.40,1)*100)*Inputs!$C$13
+ (MIN(MAX(J4,0)/0.30,1)*100)*Inputs!$C$14
Every input is capped at 100 so a name running unusually hot on one pillar does not dominate the composite. The score lands in the 0 to 100 range with clear tier breaks at 70, 50, and 30.
Reading the Dashboard
The Dashboard sheet has 14 columns: symbol, name, sector, price, R&D % of revenue, R&D dollars, gross margin, operating margin, revenue growth, ROIC, EV/EBITDA, P/E, Moat Score, and R&D Tag. Conditional formatting turns each metric into a heatmap so you can spot patterns at a glance.
| Tag | R&D / Revenue | Typical Profile |
|---|---|---|
| High R&D | Above 15% | Semis, biotech, AI software platforms |
| Moderate | 8% to 15% | Hyperscalers, mature software, medtech |
| Low | Below 8% | Industrials, energy, defense |
The Tag column is purely a categorical bucket. The Moat Score is the analytical workhorse: it integrates all four pillars and reflects whether the R&D spending is supported by the rest of the business.
What High-Intensity, High-Quality Names Look Like
The names that consistently end up in Tier 1 of the Moat Score share a few traits:
- R&D intensity above 12% of revenue
- Gross margin above 60%
- Operating margin above 25%
- ROIC above 20%
- Revenue growth above 15%
That is a high bar. A handful of names hit it: large-cap software with platform economics, leading semis with pricing power, and a small set of biotech franchises. The screener is designed to surface these names without making you do the cross-referencing manually.
What to Watch Out For
The screener will also surface a few patterns that look attractive on intensity alone but fail the other tests:
- R&D running ahead of revenue. A name lifting R&D intensity from 20% to 25% while revenue stalls is on a research treadmill. The Moat Score will pull this down via the growth pillar.
- R&D dollars rising while gross margin falls. This often signals a competitive response to share loss rather than an offensive moat investment. The profitability pillar catches it.
- High R&D, low ROIC. Common in pre-product biotechs and unprofitable software. These names can still appreciate, but they fail the capital efficiency test and rank as Tier 3 or 4.
The screener does not tell you the future. It tells you which names are currently funding their innovation moat from a durable margin base. That is a starting filter, not a buy list.
Sample Output: How the May 2026 Dashboard Looks
A snapshot of the 30-name dashboard sorted by Moat Score (Tier 1 only):
| Symbol | R&D / Rev | Gross M | Op M | Rev Growth | ROIC | Moat Score |
|---|---|---|---|---|---|---|
| NVDA | 11.5% | 75.2% | 63.8% | 72.5% | 72.5% | 90+ |
| META | 27.5% | 81.5% | 42.5% | 21.5% | 28.5% | 80+ |
| LLY | 22.5% | 82.5% | 42.8% | 42.5% | 42.5% | 80+ |
| AVGO | 14.2% | 74.1% | 44.5% | 38.5% | 18.5% | 75+ |
| MSFT | 12.8% | 69.8% | 43.5% | 15.5% | 22.5% | 70+ |
| GOOGL | 14.5% | 58.5% | 32.4% | 14.2% | 22.5% | 70+ |
Tier 1 names share elevated R&D intensity, strong margins, sustained growth, and ROIC well into the double digits. The dashboard also surfaces names like INTC with high R&D intensity (close to 30%) but negative operating margin, which the Moat Score correctly demotes to Tier 4 even though intensity alone would have flagged it as a leader.
The R&D Trend Sheet: 5 Years of Intensity History
The R&D Trend sheet pulls five years of R&D-to-revenue history for a curated subset of names so you can see whether the intensity story is improving, stable, or fading:
FY2021: =HF_RANDD_EXPENSE_AS_PERCENTAGE_OF_REVENUE("META", 2021)
FY2022: =HF_RANDD_EXPENSE_AS_PERCENTAGE_OF_REVENUE("META", 2022)
FY2023: =HF_RANDD_EXPENSE_AS_PERCENTAGE_OF_REVENUE("META", 2023)
FY2024: =HF_RANDD_EXPENSE_AS_PERCENTAGE_OF_REVENUE("META", 2024)
FY2025: =HF_RANDD_EXPENSE_AS_PERCENTAGE_OF_REVENUE("META", 2025)
The interpretation column tags each row as Leaning In (rising intensity), Stable Commitment (flat), or Harvesting / Cutting (falling). The most interesting tells are the names that move between categories: a Stable Commitment name that flips to Leaning In often coincides with a new product cycle, and a Leaning In name that flips to Stable often coincides with a margin inflection.
How to Customize the Screener
The Inputs sheet drives every formula in the workbook. You can rebalance the screener without touching any other sheet:
| Input | Default | What It Does |
|---|---|---|
| Portfolio Size | $100,000 | Drives the Portfolio Allocation sheet |
| Max Position Size | 10% | Position cap on the top-ranked names |
| Min R&D / Revenue | 8% | First-pass filter on the intensity tag |
| Min Gross Margin | 40% | Quality floor |
| Min ROIC | 10% | Capital efficiency floor |
| High R&D Threshold | 15% | Cutoff for High Intensity tag |
| Moderate R&D Threshold | 8% | Cutoff for Moderate tag |
| Score: R&D Weight | 30% | Composite weight for intensity |
| Score: Profitability Weight | 25% | Composite weight for margins |
| Score: Growth Weight | 25% | Composite weight for revenue growth |
| Score: Capital Eff Weight | 20% | Composite weight for ROIC |
Changing any yellow input cell ripples through the dashboard, the Moat Score sheet, the portfolio allocation, and the sector roll-up. There is no macro to run.
Portfolio Allocation: Top 8 Sized to Score
The Portfolio Allocation sheet takes the top 8 Moat Score names and sizes positions using two rules:
- Each position is capped at the max position size (default 10% of portfolio).
- Within the cap, each name is weighted proportionally to its share of total Moat Score.
A name with a Moat Score of 85 and a name with a Moat Score of 60 do not get equal weight; the higher-conviction name takes more. The final allocation column shows the dollar value and final share count, and a totals block at the bottom shows the cash reserve and percent of portfolio deployed.
Sector R&D Comparison: Where the Stories Cluster
The final sheet rolls watchlist names up by GICS sector. For each sector it shows:
- Number of watchlist names in the sector
- Count of High R&D names
- Count of Moderate names
- Count of Low names
- Sector R&D Score = (High * 100 + Moderate * 50) / Names
In May 2026 the Sector R&D Score concentrates near the top in Information Technology, Communication Services, and Healthcare. Industrials and Energy show up at the bottom. That clustering is not surprising, but the sheet makes it easy to see which sectors are doing the work and which are not.
How This Fits with Other MarketXLS Screeners
The research and development screener Excel sits alongside several other quality screens built in MarketXLS:
- The GARP screener blends growth and valuation.
- The Quality Compounders screener focuses on ROIC and ROE.
- The Pricing Power screener emphasizes gross margin durability.
- The Operating Leverage screener tracks revenue-to-earnings amplification.
- The AI Capex Tracker zeroes in on hyperscaler capital spending.
Each takes a different slice. The R&D screener is the cleanest for surfacing innovation-funded compounders; pair it with the AI Capex Tracker to separate companies funding research from companies funding infrastructure.
Download the Templates
Both files include the full 30-name watchlist, Innovation Moat Score, R&D Trend sheet, Portfolio Allocation, and Sector Comparison.
Download the templates:
- - pre-filled with snapshot data as of May 15, 2026. Opens without a MarketXLS subscription and shows the exact formula syntax in the Functions Used box on every sheet.
- - live formulas pull fresh fundamentals every time you press refresh. Requires an active MarketXLS add-in.
Frequently Asked Questions
What is a research and development screener Excel template used for?
A research and development screener Excel template ranks publicly traded companies by how much they invest in R&D relative to their revenue, and combines that with profitability, growth, and capital efficiency to surface candidates with a sustainable innovation moat. It is a quality screen: the goal is to find names that fund their research from a durable margin base rather than burning cash on a research treadmill.
What is a good R&D intensity ratio?
There is no single threshold. Software and semiconductors routinely spend 15% to 25% of revenue on R&D and consider that normal; consumer staples and energy companies often spend below 2%. The screener defaults to a High R&D tag above 15% and a Moderate tag between 8% and 15%, but the more useful signal is the composite Innovation Moat Score, which scales intensity against profitability, growth, and ROIC together.
Which MarketXLS function returns R&D as a percentage of revenue?
The function is =HF_RANDD_EXPENSE_AS_PERCENTAGE_OF_REVENUE("Symbol", Year). It returns the R&D-to-revenue ratio for the fiscal year you specify, expressed as a percentage. For the raw dollar amount, use =HF_RANDD_EXPENSES("Symbol", Year). Both functions accept any common large-cap ticker and are documented in the MarketXLS Function Reference.
Why pair R&D intensity with gross margin and ROIC?
R&D intensity alone is incomplete. A company spending 25% of revenue on R&D but earning a 30% gross margin is in a structurally different position than one spending 25% with a 75% gross margin. The first is on a research treadmill; the second has the cushion to keep investing. ROIC adds a capital-efficiency overlay so the screen does not reward companies that burn capital. The composite Moat Score blends all three lenses into a single ranking.
Can I add or remove names from the watchlist?
Yes. The watchlist sits on the R&D Dashboard sheet in the Symbol column. Replace any ticker and every MarketXLS formula on the row resolves automatically. The R&D Trend sheet uses a curated subset of ten names; you can swap those by editing the ticker and the fiscal-year arguments inside HF_RANDD_EXPENSE_AS_PERCENTAGE_OF_REVENUE.
How is the Innovation Moat Score calculated?
The composite is a weighted sum of four sub-scores (each scaled to 0 to 100):
- R&D Intensity Score - R&D / Revenue scaled against a 30% ceiling
- Profitability Score - average of gross margin (vs 80% ceiling) and operating margin (vs 40% ceiling)
- Growth Score - revenue growth scaled against a 40% ceiling
- Capital Efficiency Score - ROIC scaled against a 30% ceiling
Default weights are 30% / 25% / 25% / 20%. All four weights live in the Inputs sheet and can be edited. The composite lands in the 0 to 100 range with tier breaks at 70, 50, and 30.
What is the difference between the static sample and the live template?
The sample workbook is pre-filled with a May 15, 2026 snapshot so it opens and renders without any add-in. It includes the same Functions Used box on each sheet so you can see exactly which MarketXLS formula powers each value. The template version replaces the static values with live MarketXLS formulas; every press of refresh fetches fresh fundamentals.
The Bottom Line
The research and development screener Excel template translates a classic quality screen into a single ranked watchlist, scoring each name on four pillars that matter together: research intensity, margin durability, growth, and capital efficiency. In an environment where AI capex is dominating earnings calls and tariffs are compressing margins, the names that fund their research moat from a durable margin base are the ones that compound through the noise. The screener surfaces them without forcing you to do the cross-referencing yourself.
Both Excel files above are yours to download and customize. The static version opens anywhere; the live version updates with every refresh once the MarketXLS add-in is installed. Pair this screener with the GARP, Quality Compounders, and AI Capex screeners linked above for a more complete view of innovation-funded compounders.
Learn more about building Excel-based equity research workflows at marketxls.com, or book a demo to see the platform in action.
